对此北京地坛医院中西医结合科主任医师王融冰介绍，第六版诊疗方案重点推荐了清肺排毒汤通治型的 方剂，对中药方剂的煎煮法进行了比较细致的说明，对中药注射剂的使用方法、剂量都有详细说明，使 第六版方案更具有指导性和实用性。 对于中药治疗的疗效，王融冰表示，现在中西医结合的覆盖面非常大，通过前一阶段治疗效果和后一阶 段中药介入后的治疗效果比较，发现中药的参与，中西医结合治疗确实起到比较好的作用。 对于轻症病人，用中药以后迅速改善了发热症状或减轻了咳嗽症状，使其病情不再往重症发展，对于病 人抗病有非常大的助力。对于重症期使用中医药不但可以改善这些症状，对和呼吸相关的指标，比如血 氧饱和度等也有一定改善，这就阻断了病情继续向危重症发展的过程，降低了危重症的发病率，同时也 就等于降低了病死率。 王融冰强调，医学观察期推荐治疗的是有症状的人，"有些人感到虚弱、乏力，甚至有些人有腹泻，我 们推荐了中成药藿香正气水、正气散、正气丸等等。有些觉得自己有点不舒服，甚至有点发热，也推荐 了一些具有清热作用的中成药，这些药物的使用并不是为了预防，所以不主张没有症状的人使用中成药 预防，这没有意义。" 每经记者｜张蕊 每经编辑｜陈旭 2月 ...

Core Insights - Community-acquired pneumonia (CAP) is a common type of lower respiratory tract infection with high incidence and significant harm, particularly among the elderly in China due to the aging population [1][3] Group 1: Disease Characteristics - CAP in the elderly often presents atypical symptoms such as decreased appetite, fatigue, confusion, and urinary incontinence, which can lead to delayed diagnosis [3] - The incidence of elderly CAP shows seasonal fluctuations, with higher rates in Northeast and East China, particularly during autumn and winter [3] - Elderly pneumonia has unique characteristics, including insidious onset, atypical symptoms, rapid progression, and multiple complications [3][4] Group 2: Treatment Approaches - The distribution of pathogens in elderly CAP is characterized by a predominance of Gram-negative bacilli, especially in older patients, with a high risk of mixed infections and antibiotic resistance [4] - Treatment should be based on the unique pathophysiological features of elderly pneumonia, initiating empirical anti-infection therapy early and adjusting treatment based on pneumonia type and severity [4] - New classes of antibiotics can significantly shorten treatment duration and reduce hospital stay, alleviating the healthcare burden [4] Group 3: Prevention Strategies - Vaccination is highlighted as the most cost-effective preventive measure, with recommendations for elderly individuals to receive pneumococcal and seasonal influenza vaccines [6] - Maintaining good hygiene practices, such as handwashing and wearing masks, is essential to reduce infection risk [6] - Additional preventive measures include proper eating posture for those with swallowing difficulties, maintaining oral hygiene, balanced nutrition, and moderate exercise to enhance immunity [6]

Core Insights - The flu activity in China is on the rise, with significant increases in flu-related consultations reported, particularly in southern and northern provinces, indicating a widespread flu epidemic [1] - The demand for antiviral traditional Chinese medicine (TCM) is surging due to the high incidence of respiratory diseases, with hospital visits increasing by approximately 30%-50% year-on-year [3] - The combination of Western and traditional Chinese medicine is becoming a mainstream treatment approach for respiratory infections, leveraging the strengths of both medical systems [4] Industry Demand - The market for antiviral TCM is experiencing a sharp increase in demand, with reports of stock shortages for popular antiviral products in some regions [3][4] - The RSV (Respiratory Syncytial Virus) is prevalent among severe acute respiratory infection cases, particularly in children, creating a complex dual epidemic situation alongside the flu [3] Product Insights - The compound Qilan oral solution, derived from traditional formulations, exhibits both antiviral properties and immune regulation capabilities, making it particularly relevant in the context of mixed infections [5][8] - The product's multi-component and multi-target action mechanism helps regulate immune responses while alleviating core symptoms such as fever and cough [8] Company Operations - Zhenbaodao Pharmaceutical, a leading TCM company, is ramping up production to meet the increasing demand for antiviral products, ensuring a stable supply chain through rigorous quality control measures [8] - The company emphasizes the importance of maintaining high standards in the sourcing and production of raw materials to ensure product efficacy and reliability [8]

Core Insights - The 12th Academic Conference of the Ophthalmology Professional Committee of Hubei Traditional Chinese Medicine Association was held in Enshi City, focusing on the theme "Inheritance and Innovation, Integration for a Bright Future" to promote the development of ophthalmology and traditional Chinese medicine [1][2] Group 1: Conference Highlights - The conference featured renowned experts sharing the latest research findings and clinical experiences, including Professor Kang Zefeng and Professor Xing Yiqiao [1] - An innovative segment titled "Jingming Lunjian: Master’s Diagnosis" allowed ophthalmology experts from various regions to present typical cases and treatment techniques, including a live diagnosis and treatment for a 64-year-old patient [1] Group 2: Educational Initiatives - A "Classics Understanding - Traditional Chinese Ophthalmology Knowledge Competition" was organized to assess participants' understanding of classical literature and clinical applications, enhancing professional skills [2] - In the "Diligent Learning Techniques - New Technology Exchange" section, experts discussed topics such as "Balanced Immunity, Optimal Protection" and "Clinical Application of Integrated Chinese and Western Medicine in Dry Eye Treatment" [2] Group 3: Institutional Progress - Enshi Central Hospital has made significant advancements in medical technology, research innovation, talent cultivation, and service capabilities in ophthalmology, becoming the first national clinical key specialty in the region [2] - The hospital aims to continue enhancing its research and clinical service levels, particularly in areas like myopia prevention, cataract recovery, and refractive surgery, contributing to the health of Enshi and Hubei [2]

Core Insights - A groundbreaking achievement in treating Type 1 diabetes mellitus (T1DM) has been reported by Professor An Chiying and her team at Shenzhen Hengsheng Hospital, where 24 patients have successfully discontinued insulin therapy through holistic integrative medicine (HIM) since June 2024, with the longest insulin-free duration reaching 14 months [1][5] Group 1: Treatment Methodology - The HIM model combines traditional Chinese medicine (TCM), orthomolecular medicine, functional medicine, and lifestyle medicine, focusing on immune blockade and metabolic balance, alongside precision remote digital healthcare to restore islet function [2][3] - The treatment protocol involves multidisciplinary collaboration, including precision diagnostics, immune regulation through molecular nutrition and TCM, metabolic repair via acupuncture and herbal medicine, and precision monitoring using artificial intelligence for personalized treatment adjustments [3] Group 2: Clinical Outcomes - Over a two-year observation period, 70 T1DM patients were treated, with 24 patients (34%) completely discontinuing insulin use while maintaining stable blood glucose levels (HbA1c < 7%) and showing significant recovery of islet function as indicated by C-peptide testing [5][6] - Patients diagnosed early with T1DM and having a C-peptide level above 0.5 ng/ml can stop insulin, while those with lower islet function can significantly reduce insulin dosage once blood glucose levels are stabilized [6] Group 3: Expert Evaluation and Implications - Academician Fan Daiming of the Chinese Academy of Engineering praised the results, stating that they challenge the traditional view of lifelong medication for T1DM and highlight the potential of HIM as a new clinical treatment paradigm [7] - The global T1DM patient population is approximately 9 million, with traditional treatment costs exceeding RMB 10,000 annually, indicating that HIM could alleviate both financial and health burdens on patients [7]

Core Viewpoint - The increasing incidence of cancer among the elderly in China poses a significant challenge for health management, necessitating personalized treatment approaches and early screening initiatives to improve outcomes for this demographic [1][2][10]. Group 1: Cancer Incidence and Characteristics - The proportion of new cancer cases among individuals aged 60 and above in China is 60.7% [1]. - Common malignancies in the elderly include lung cancer and digestive system cancers, accounting for approximately 65% of new cases in this age group [2]. - Factors contributing to cancer in older adults include age-related genetic mutations and the accumulation of carcinogenic factors over time [2][4]. Group 2: Treatment Approaches - There is a tendency among elderly patients to seek unverified remedies or to avoid conventional treatments due to misconceptions about the effects of surgery and chemotherapy [4]. - Personalized treatment plans are essential, taking into account the unique health status and treatment preferences of elderly patients [4]. - Both Western medicine, including targeted therapies and immunotherapy, and traditional Chinese medicine (TCM) play important roles in treating elderly cancer patients [6][8]. Group 3: Quality of Life and Supportive Care - Enhancing the quality of life for cancer patients can lead to improved survival rates [5]. - TCM practices, such as herbal remedies and acupuncture, have been shown to alleviate discomfort during chemotherapy and radiotherapy [8][9]. - Hospitals are developing unique TCM formulations to address specific symptoms associated with cancer treatments [9]. Group 4: Prevention and Early Detection - Early screening and diagnosis are critical for effective cancer management in the elderly [10]. - Initiatives are underway in various regions to provide free cancer screenings for older adults, targeting high-risk populations [10]. - Lifestyle modifications, including balanced nutrition and physical activity, are recommended to enhance the overall health and resilience of elderly individuals [10].

Core Viewpoint - The conference focused on the relationship between depression and insomnia, highlighting the importance of integrated treatment approaches using both traditional Chinese medicine and Western medicine to improve patient outcomes [1][2][4]. Group 1: Conference Overview - The "Chronic Disease Prevention and Treatment in China" conference was held on June 21, combining online and offline formats across Changsha, Wuhan, and Guangzhou, attracting hundreds of experts in mental health [1]. - Professor Zhang Honggeng presented a report on the understanding of "depression and insomnia" from both Chinese and Western medical perspectives, emphasizing the clinical effectiveness of innovative Chinese herbal medicines [1][3]. Group 2: Relationship Between Depression and Insomnia - Depression is characterized by persistent low mood lasting at least two weeks, while insomnia involves difficulty in falling or maintaining sleep for 2-3 weeks, both of which are interrelated [2]. - Approximately 40%-90% of depression patients experience insomnia symptoms, and 71.7% of those treated with antidepressants still have residual insomnia symptoms [2]. - Insomnia increases the risk of developing depression by 183%, anxiety disorders by 223%, and suicide risk by 67%, indicating a bidirectional relationship between the two conditions [2]. Group 3: Treatment Approaches - The conference highlighted the unique advantages of traditional Chinese medicine in identifying and treating depression and insomnia through personalized treatment plans [2][4]. - Innovative Chinese herbal medicines such as "Jieyu Chufan Capsule" and "Yishen Yangxin Anshen Tablet" were discussed for their significant clinical applications in treating different types of depression and insomnia [4]. - The "Jieyu Chufan Capsule" is effective for patients with symptoms like dizziness, chest tightness, and anxiety, while the "Yishen Yangxin Anshen Tablet" is recommended for patients with insomnia due to deficiency syndromes [4]. Group 4: Integration of Treatment Methods - The necessity of combining traditional Chinese and Western medicine for treating depression and insomnia was emphasized, as this approach can enhance treatment efficacy and reduce side effects [4].

Core Viewpoint - The newly released "Guidelines for Percutaneous Coronary Intervention (2025)" recommend the use of Tongxinluo for treating acute coronary syndrome, particularly in patients undergoing interventional treatment, highlighting its efficacy in anti-myocardial ischemia and improving no-reflow and reperfusion injury [1][4]. Group 1: Guidelines Overview - The guidelines were initiated by the Chinese Medical Association's Cardiovascular Disease Branch and the Editorial Committee of the Chinese Journal of Cardiovascular Diseases, with contributions from over 60 cardiovascular experts [3]. - The guidelines provide strict indications and standardized implementation for PCI in China, ensuring patient safety [3]. Group 2: Efficacy of Tongxinluo - Tongxinluo, developed under the theory of collateral disease, has demonstrated significant effects in protecting ischemic tissues, reducing lipid levels, and stabilizing vulnerable plaques [4][5]. - Clinical trials indicate that Tongxinluo can reduce the incidence of no-reflow by 36.6% and lower the 30-day adverse cardiovascular event rate by 36% [5]. Group 3: Efficacy of Qiyuqiangxin - Qiyuqiangxin is recommended for patients with heart failure, particularly those with low blood pressure, as it does not adversely affect blood pressure while improving cardiac function [6]. - Research shows that adding Qiyuqiangxin to standard heart failure treatment can reduce the risk of composite cardiovascular events by 22% [6]. Group 4: Integration of Traditional Chinese Medicine - The guidelines mark a significant breakthrough for Traditional Chinese Medicine (TCM) in coronary intervention, incorporating Tongxinluo and Qiyuqiangxin into treatment recommendations [8]. - Experts emphasize the value of TCM in treating coronary heart disease, showcasing its potential in modern medical practices [8].